| Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis (NCT05342428) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2022-06-10 |
| 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (NCT05155098) | Novartis Pharmaceuticals | 2022-03-25 |
| Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis (NCT05258331) | GC Cell Corporation | 2021-10-25 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis (NCT05020249) | UCB Biopharma SRL | 2021-09-27 |
| Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis (NCT04999839) | Takeda | 2021-08-11 |
| A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis (NCT04967508) | Samsung Bioepis Co., Ltd. | 2021-07-06 |
| Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis (NCT04839016) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-25 |
| A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis (NCT04718896) | UCB Biopharma SRL | 2021-04-06 |
| To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis (NCT04566666) | Sun Pharmaceutical Industries Limited | 2021-03-25 |
| A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (NCT04612699) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-03-11 |
| A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis (NCT04614298) | Kyowa Kirin Co., Ltd. | 2021-01-01 |
| A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting (NCT05787236) | Novartis Pharmaceuticals | 2020-11-05 |
| Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects (NCT04367441) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2019-11-25 |
| A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis (NCT03710681) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-02 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT03412747) | UCB Biopharma SRL | 2018-01-26 |
| An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (NCT03390101) | Biocad | 2017-12-26 |
| Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients (NCT03146247) | Diamant Thaci | 2017-10-23 |
| A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea (NCT02982005) | Kyowa Kirin Korea Co., Ltd. | 2017-01-01 |
| A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece (NCT02713295) | AbbVie | 2016-06-16 |
| MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (NCT02660580) | Fresenius Kabi SwissBioSim GmbH | 2016-02-16 |
| Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis (NCT02607774) | Novartis Pharmaceuticals | 2015-12-17 |
| A Phase 2 Clinical Study of KHK4827 (NCT01748539) | Kyowa Kirin Co., Ltd. | 2012-12-01 |
| P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (NCT01708603) | Bausch Health Americas, Inc. | 2012-08-01 |
| An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation (NCT01644396) | AbbVie (prior sponsor, Abbott) | 2012-05-01 |
| Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis (NCT01622348) | Idera Pharmaceuticals, Inc. | 2012-05-01 |
| Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (NCT01401452) | AbbVie (prior sponsor, Abbott) | 2011-08-01 |
| An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis (NCT01555606) | Janssen Biotech, Inc. | 2011-06-01 |
| Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates. (NCT01260844) | Abbott | 2011-04-01 |
| Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (NCT01202565) | AbbVie (prior sponsor, Abbott) | 2010-09-01 |
| Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT00710580) | AbbVie (prior sponsor, Abbott) | 2008-07-01 |
| Open Label Continuation Study in Moderate to Severe Psoriasis (NCT00626002) | AbbVie (prior sponsor, Abbott) | 2008-02-01 |
| Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (NCT01077232) | AbbVie (prior sponsor, Abbott) | 2008-01-04 |